Pharmacokinetics of bupropion and its pharmacologically active metabolites in pregnancy

Valentina Fokina, Meixiang Xu, Erik Rytting, Sherif Abdel-Rahman, Holly West, Cheryl Oncken, Shannon Clark, Mahmoud Ahmed, Gary Hankins, Tatiana Nanovskaya

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Bupropion sustained release is used to promote smoking cessation in males and nonpregnant females. However, its efficacy as a smoking cessation aid during pregnancy is not reported. The pregnancy-associated changes in maternal physiology may alter the pharmacokinetics and pharmacodynamics of bupropion and consequently its efficacy in pregnant smokers. Therefore, the aims of this study were to determine the steady-state pharmacokinetics of bupropion during pregnancy and the effect of functional genetic variants of CYP2B6 and CYP2C19 on bupropion pharmacokinetics in pregnant women. Plasma and urine concentrations of bupropion and its metabolites hydroxybupropion (OHBUP), threohydrobupropion, and erythrohydrobupropion were determined by liquid chromatography-mass spectrometry. Subjects were genotyped for five nonsynonymous single-nucleotide polymorphisms that result in seven CYP2B6 alleles, namely ∗2, ∗3, ∗4, ∗5, ∗6, ∗7, and ∗9, and for CYP2C19 variants ∗2, ∗3, and ∗17. The present study reports that the isoform-specific effect of pregnancy on bupropion-metabolizing enzymes along with the increase of renal elimination of the drug could collectively result in a slight decrease in exposure to bupropion in pregnancy. In contrast, pregnancy-induced increase in CYP2B6-catalyzed bupropion hydroxylation did not impact the plasma levels of OHBUP, probably due to a higher rate of OHBUP glucuronidation, and renal elimination associated with pregnancy. Therefore, exposure to OHBUP, a pharmacologically active metabolite of the bupropion, appears to be similar to that of the nonpregnant state. The predicted metabolic phenotypes of CYP2B6∗6 and variant alleles of CYP2C19 in pregnancy are similar to those in the nonpregnant state.

Original languageEnglish (US)
Pages (from-to)1832-1838
Number of pages7
JournalDrug Metabolism and Disposition
Volume44
Issue number11
DOIs
StatePublished - 2016

Fingerprint

Bupropion
Pharmacokinetics
Pregnancy
Smoking Cessation
Alleles
Hydroxylation
Liquid Chromatography
Single Nucleotide Polymorphism
Pregnant Women
Mass Spectrometry
Protein Isoforms
Mothers
Urine
Phenotype

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

Pharmacokinetics of bupropion and its pharmacologically active metabolites in pregnancy. / Fokina, Valentina; Xu, Meixiang; Rytting, Erik; Abdel-Rahman, Sherif; West, Holly; Oncken, Cheryl; Clark, Shannon; Ahmed, Mahmoud; Hankins, Gary; Nanovskaya, Tatiana.

In: Drug Metabolism and Disposition, Vol. 44, No. 11, 2016, p. 1832-1838.

Research output: Contribution to journalArticle

@article{904c5723d88c4c1da3f7f968adf97842,
title = "Pharmacokinetics of bupropion and its pharmacologically active metabolites in pregnancy",
abstract = "Bupropion sustained release is used to promote smoking cessation in males and nonpregnant females. However, its efficacy as a smoking cessation aid during pregnancy is not reported. The pregnancy-associated changes in maternal physiology may alter the pharmacokinetics and pharmacodynamics of bupropion and consequently its efficacy in pregnant smokers. Therefore, the aims of this study were to determine the steady-state pharmacokinetics of bupropion during pregnancy and the effect of functional genetic variants of CYP2B6 and CYP2C19 on bupropion pharmacokinetics in pregnant women. Plasma and urine concentrations of bupropion and its metabolites hydroxybupropion (OHBUP), threohydrobupropion, and erythrohydrobupropion were determined by liquid chromatography-mass spectrometry. Subjects were genotyped for five nonsynonymous single-nucleotide polymorphisms that result in seven CYP2B6 alleles, namely ∗2, ∗3, ∗4, ∗5, ∗6, ∗7, and ∗9, and for CYP2C19 variants ∗2, ∗3, and ∗17. The present study reports that the isoform-specific effect of pregnancy on bupropion-metabolizing enzymes along with the increase of renal elimination of the drug could collectively result in a slight decrease in exposure to bupropion in pregnancy. In contrast, pregnancy-induced increase in CYP2B6-catalyzed bupropion hydroxylation did not impact the plasma levels of OHBUP, probably due to a higher rate of OHBUP glucuronidation, and renal elimination associated with pregnancy. Therefore, exposure to OHBUP, a pharmacologically active metabolite of the bupropion, appears to be similar to that of the nonpregnant state. The predicted metabolic phenotypes of CYP2B6∗6 and variant alleles of CYP2C19 in pregnancy are similar to those in the nonpregnant state.",
author = "Valentina Fokina and Meixiang Xu and Erik Rytting and Sherif Abdel-Rahman and Holly West and Cheryl Oncken and Shannon Clark and Mahmoud Ahmed and Gary Hankins and Tatiana Nanovskaya",
year = "2016",
doi = "10.1124/dmd.116.071530",
language = "English (US)",
volume = "44",
pages = "1832--1838",
journal = "Drug Metabolism and Disposition",
issn = "0090-9556",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "11",

}

TY - JOUR

T1 - Pharmacokinetics of bupropion and its pharmacologically active metabolites in pregnancy

AU - Fokina, Valentina

AU - Xu, Meixiang

AU - Rytting, Erik

AU - Abdel-Rahman, Sherif

AU - West, Holly

AU - Oncken, Cheryl

AU - Clark, Shannon

AU - Ahmed, Mahmoud

AU - Hankins, Gary

AU - Nanovskaya, Tatiana

PY - 2016

Y1 - 2016

N2 - Bupropion sustained release is used to promote smoking cessation in males and nonpregnant females. However, its efficacy as a smoking cessation aid during pregnancy is not reported. The pregnancy-associated changes in maternal physiology may alter the pharmacokinetics and pharmacodynamics of bupropion and consequently its efficacy in pregnant smokers. Therefore, the aims of this study were to determine the steady-state pharmacokinetics of bupropion during pregnancy and the effect of functional genetic variants of CYP2B6 and CYP2C19 on bupropion pharmacokinetics in pregnant women. Plasma and urine concentrations of bupropion and its metabolites hydroxybupropion (OHBUP), threohydrobupropion, and erythrohydrobupropion were determined by liquid chromatography-mass spectrometry. Subjects were genotyped for five nonsynonymous single-nucleotide polymorphisms that result in seven CYP2B6 alleles, namely ∗2, ∗3, ∗4, ∗5, ∗6, ∗7, and ∗9, and for CYP2C19 variants ∗2, ∗3, and ∗17. The present study reports that the isoform-specific effect of pregnancy on bupropion-metabolizing enzymes along with the increase of renal elimination of the drug could collectively result in a slight decrease in exposure to bupropion in pregnancy. In contrast, pregnancy-induced increase in CYP2B6-catalyzed bupropion hydroxylation did not impact the plasma levels of OHBUP, probably due to a higher rate of OHBUP glucuronidation, and renal elimination associated with pregnancy. Therefore, exposure to OHBUP, a pharmacologically active metabolite of the bupropion, appears to be similar to that of the nonpregnant state. The predicted metabolic phenotypes of CYP2B6∗6 and variant alleles of CYP2C19 in pregnancy are similar to those in the nonpregnant state.

AB - Bupropion sustained release is used to promote smoking cessation in males and nonpregnant females. However, its efficacy as a smoking cessation aid during pregnancy is not reported. The pregnancy-associated changes in maternal physiology may alter the pharmacokinetics and pharmacodynamics of bupropion and consequently its efficacy in pregnant smokers. Therefore, the aims of this study were to determine the steady-state pharmacokinetics of bupropion during pregnancy and the effect of functional genetic variants of CYP2B6 and CYP2C19 on bupropion pharmacokinetics in pregnant women. Plasma and urine concentrations of bupropion and its metabolites hydroxybupropion (OHBUP), threohydrobupropion, and erythrohydrobupropion were determined by liquid chromatography-mass spectrometry. Subjects were genotyped for five nonsynonymous single-nucleotide polymorphisms that result in seven CYP2B6 alleles, namely ∗2, ∗3, ∗4, ∗5, ∗6, ∗7, and ∗9, and for CYP2C19 variants ∗2, ∗3, and ∗17. The present study reports that the isoform-specific effect of pregnancy on bupropion-metabolizing enzymes along with the increase of renal elimination of the drug could collectively result in a slight decrease in exposure to bupropion in pregnancy. In contrast, pregnancy-induced increase in CYP2B6-catalyzed bupropion hydroxylation did not impact the plasma levels of OHBUP, probably due to a higher rate of OHBUP glucuronidation, and renal elimination associated with pregnancy. Therefore, exposure to OHBUP, a pharmacologically active metabolite of the bupropion, appears to be similar to that of the nonpregnant state. The predicted metabolic phenotypes of CYP2B6∗6 and variant alleles of CYP2C19 in pregnancy are similar to those in the nonpregnant state.

UR - http://www.scopus.com/inward/record.url?scp=85015381063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015381063&partnerID=8YFLogxK

U2 - 10.1124/dmd.116.071530

DO - 10.1124/dmd.116.071530

M3 - Article

VL - 44

SP - 1832

EP - 1838

JO - Drug Metabolism and Disposition

JF - Drug Metabolism and Disposition

SN - 0090-9556

IS - 11

ER -